Lagta hai, Ek member ki repeatedly Behudgi ki bajah se Aniketiaf sir ne forum par aana band kar diya hai.
85.2. ColdBurger| Link| Bookmark|
December 15, 2021 10:07:52 AM
IPO Mentor (1300+ Posts, 400+ Likes)
It is really sad to miss opinion of one of the most respected members during IPO Mela. His opinion matters a lot. Hope he reconsiders to start posting here again @#Aniketiaf
Good to see Employees are going for it... and it is more then 1.7x at the moment...
not sure about the price moment after listing... all depends on market.. but will it have advantage when Pharmeasy IPO will come... so can buy for short term to medium term once price stable???
For its eligible employees offering them a discount of Rs. 78 per share. 10 % discount to employees.
82. ipobull| Link| Bookmark|
December 14, 2021 9:39:06 PM
IPO Guru (1000+ Posts, 1000+ Likes)
I am applying in both MedPlus and Data Patterns. But anyone having cash crunch, Data Patterns will give better returns, but chances of allotment will be less.
82.1. SamJos| Link| Bookmark|
December 15, 2021 2:24:49 AM
Top Contributor (500+ Posts, 100+ Likes)
Returns depends on not only on gmp, but also on subscription figures. It is always chase to decide between high gmp*high subsc (Data) vs low gmp*low subsc (Medplus), & ultimate smile remains of Lady Luck. I will monitor sub figures & experts talk at 2.30 tomorrow & decide to go retail or hni.
81. K.Atar| Link| Bookmark|
December 14, 2021 8:37:25 PM
IPO Guru (1000+ Posts, 700+ Likes)
C.E. INFO S Rs 1,080/- {+/- Rs 10/-} DATA PAT Rs 610/- {+/- Rs 10} SUPRIYA Rs 275/- {+/- Rs 10/-} MEDPLUS Rs 175/- {+/- Rs 5/-}
Apply IPO(s) at your own discretion.
81.1. SamJos| Link| Bookmark|
December 15, 2021 1:59:07 AM
Top Contributor (500+ Posts, 100+ Likes)
The way gmp is decreasing on 2nd day, it might remain only 10% or less reaching listing :(
80. SSingh| Link| Bookmark|
December 14, 2021 9:26:39 PM
IPO Guru (1400+ Posts, 800+ Likes)
This would have been subscribed atleast 20X in retail if other IPOs were not there. Good IPO for listing/short and even long term. If you have funds, it’s a no-brainer. If you have funds only for 1 IPO, choose Data as it will be give you bumper listing gains!
Looks like most retailers, like me, are facing cash crunch here, as all the money has been employed in Map. That''s why this segment is not showing encouraging figures (even for a 2nd day subscription, it should have been better than this) at least as of now. Seems we all are directly proceeding to DataPattern...
Wise decision is to prefer MedPlus over data pattern....don''t go by GMP....most of hni in my group will also prefer MedPlus over data patern due to cash crunch....Homework needed to be done before blindly taking decision.
@AmitJi...I had no choice but to put retail applications in both these. Hopefully I should catch Medplus with some luck. Que sera sera ... whatever will be, will be.
79.6. RJ Rocks| Link| Bookmark|
December 14, 2021 8:31:53 PM
Top Contributor (400+ Posts, 200+ Likes)
@Amit cheda I am applying 17 lot each in MapMyIndia Data pattern & medplus. Any advice should I add 1 lot Nupur by reducing medplus lots??